Kyongbo Pharmaceutical Co., Ltd

A214390

KR7214390007

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 07:00:00 2024-03-26 pm EDT			5-day change	1st Jan Change
7,440 ^KRW	-2.75%		-.--%	-11.32%

2023	Pharosgen Co., Ltd. announced that it has received KRW 1.999997692 billion in funding from Kyongbo Pharmaceutical Co., Ltd	CI
2023	Kyongbo Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	CI

Kyongbo Pharmaceutical Co., Ltd.(KOSE:A214390) added to S&P Global BMI Index

September 21, 2015 at 12:00 am EDT

Latest news about Kyongbo Pharmaceutical Co., Ltd

Pharosgen Co., Ltd. announced that it has received KRW 1.999997692 billion in funding from Kyongbo Pharmaceutical Co., Ltd	23-05-24	CI
Kyongbo Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Pharosgen Co., Ltd. announced that it expects to receive KRW 1.999997692 billion in funding from Kyongbo Pharmaceutical Co., Ltd	23-05-08	CI
Kyongbo Pharmaceutical Co., Ltd(KOSE:A214390) dropped from S&P Global BMI Index	22-09-19	CI
Can-Fite BioPharma Ltd. Signs Distribution Agreement with Kyongbo Pharm Co., Ltd	19-08-01	CI
AFT Pharmaceuticals Limited Starts to License Maxigesic IV with Deal in South Korea	18-11-05	CI
Chong Kun Dang Holdings Corp. cancelled the acquisition of an additional 6.3% stake in Kyongbo Pharmaceutical Co., Ltd..	18-04-26	CI
Chong Kun Dang Holdings Corp. agreed to acquire an additional 6.3% stake in Kyongbo Pharmaceutical Co., Ltd. for KRW 19.7 billion.	17-04-26	CI
Kyongbo Pharmaceutical Co., Ltd.(KOSE:A214390) added to MSCI Acwi + Frontier Markets(acwi Fm) All Cap Index	15-12-01	CI
Kyongbo Pharmaceutical Co., Ltd.(KOSE:A214390) added to Russell Global Index	15-10-01	CI
Kyongbo Pharmaceutical Co., Ltd.(KOSE:A214390) added to S&P Global BMI Index	15-09-21	CI
Kyongbo Pharmaceutical Co., Ltd. has completed an IPO in the amount of KRW 143.44 billion.	15-06-24	CI
Kyongbo Pharmaceutical Co. Ltd. has filed an IPO in the amount of KRW 143.45 billion.	15-05-15	CI

Chart Kyongbo Pharmaceutical Co., Ltd

Duration

Period

More charts

KYONGBO PHARMACEUTICAL CO., LTD is a Korea-based company principally engaged in manufacturing and distributing pharmaceutical products The Company operates its business through two segments: raw material medicine segment, which produces atorvastatin, ceftizoxime, ceftriaxone, clarithromycin and Pranlukast, and medicine segment, which produces surgeon respiratory solution, cefaclor capsule and cefaclor dry syrup. The Company distributes its products within domestic market and to overseas markets including China Japan and Europe.

Sector

Pharmaceuticals

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
KYONGBO PHARMACEUTICAL CO., LTD	-11.32%	131M
ELI LILLY AND COMPANY	+34.35%	705B
NOVO NORDISK A/S	+30.74%	583B
JOHNSON & JOHNSON	-3.49%	364B
MERCK & CO., INC.	+20.15%	332B
ABBVIE INC.	+6.19%	291B
ASTRAZENECA PLC	+15.75%	238B
ROCHE HOLDING AG	-3.48%	210B
NOVARTIS AG	+10.40%	209B
AMGEN INC.	+9.21%	169B

Other Pharmaceuticals